A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Doses and Dose Levels of DDP733 in Patients With Irritable Bowel Syndrome With Constipation

Inability to stop taking certain medications, or a planned change in medications (including herbal remedies) which could interfere with study assessments

Use of drugs and or ethanol which may interfere with compliance of study procedures or influence study outcome

Presence of a medical condition which could interfere with the interpretation of study data

Significant use of nicotine or caffeine

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00215566